<DOC>
	<DOCNO>NCT02589795</DOCNO>
	<brief_summary>CUTHIVAC002 randomise Phase I study aim explore safety immunogenicity two different mode delivery deoxyribonucleic acid ( DNA ) vaccine ( DNA-C CN54ENV ) via combine intramuscular intradermal method without electroporation , boost recombinant HIV CN54gp140 administer intradermal injection healthy volunteer . The aim study identify optimal DNA delivery condition promote enhance antibody response boost recombinant protein intradermal method .</brief_summary>
	<brief_title>Safety Immunogenicity HIV DNA-C CN54ENV Recombinant HIV CN54gp140 Vaccines Healthy Volunteers</brief_title>
	<detailed_description>CUTHIVAC002 randomise Phase I study healthy volunteer , aim explore safety immunogenicity two different mode delivery deoxyribonucleic acid ( DNA ) HIV vaccine via combined intramuscular intradermal method without electroporation ( EP ) , boost recombinant HIV protein vaccine administer intradermal injection without EP . The aim study identify optimal DNA delivery condition promote enhance antibody response boost recombinant protein intradermal route . Healthy male female volunteer age 18 50 year old , low risk HIV infection , recruit . The participant divide 3 group : Group 1 : Participants receive 1 x 0.15 ml ( 0.6 mg ) DNA intradermal injection upper arm EP 1 x 0.5 ml ( 2 mg ) intramuscular injection upper thigh without EP Weeks 0 , 4 &amp; 8 . And also 1 x 0.1 ml ( 50 μg ) HIV recombinant protein intradermal injection upper arm Week 20 ( final vaccination ) . Group 2 : Participants receive 1 x 0.15 ml ( 0.6 mg ) DNA intradermal injection upper arm without EP 1 x 0.5 ml ( 2 mg ) intramuscular injection upper thigh EP week 0 , 4 &amp; 8 . And also 1 x 0.1 ml ( 50 μg ) HIV recombinant protein intradermal injection upper arm Week 20 ( final vaccination ) . Group 3 : Participants receive 1 x 0.15 ml ( 0.6 mg ) DNA intradermal injection upper arm EP 1 x 0.5 ml ( 2 mg ) intramuscular injection upper thigh EP week 0 , 4 &amp; 8 . And also 1 x 0.1 ml ( 50 μg ) HIV recombinant protein intradermal injection upper arm Week 20 ( final vaccination ) . The investigator aim 8 participant complete study group .</detailed_description>
	<criteria>1 . Men woman age 18 50 year day screen 2 . BMI 1830 3 . Available followup duration study ( ~5 month screen ) 4 . Willing able give write informed consent 5 . At low risk HIV willing remain duration study define : history inject drug use previous ten year gonorrhoea syphilis last six month high risk partner ( e.g . inject drug use , HIV positive partner ) either currently within past six month unprotected anal intercourse last six month , outside relationship regular partner know HIV negative unprotected vaginal intercourse last six month outside relationship regular known/presumed HIV negative partner 6 . Willing undergo HIV test 7 . Willing undergo genital infection screen 8 . Must agree require male sexual partner use condom , least 14 day first vaccination least 14 day last 9 . If heterosexually active female capable become pregnant , must ( addition require male partner use condom ) agree use hormonal contraception , complete abstinence , least 14 day first vaccination least 14 day last . [ Note : Periodic abstinence ( e.g . calendar , ovulation , symptothermal , postovulation method ) withdrawal , IUD/IUS , acceptable method contraception . ] If sexually active male , must agree use condom day first vaccination least 14 day last . [ Note : Additional use effective method contraception recommend nonpregnant female partner period . ] 10 . Agree abstain donate blood three month end participation trial , longer necessary 11 . Registered GP least past three month 12 . Entered clearance obtain The Overvolunteering Prevention System ( TOPS ) database . 1 . Pregnant lactate 2 . History cardiac arrhythmia palpitation [ e.g. , supraventricular tachycardia , atrial fibrillation , frequent ectopy , sinus bradycardia prior study entry ( sinus arrhythmia exclude ) 3 . History syncope faint episode within 1 year study entry 4 . History grandmal epilepsy , seizure disorder history prior seizure 5 . Individuals skinfold measurement ( cutaneous subcutaneous tissue ) upper right leave thigh exceeds 40 mm 6 . Clinically relevant abnormality history examination 7 . Known hypersensitivity component vaccine formulation use trial , severe multiple allergy drug pharmaceutical agent 8 . History severe local general reaction vaccination define local : extensive , indurated redness swell involve anterolateral thigh major circumference arm , resolve within 72 hour general : fever ≥39.5 °C within 48 hour ; anaphylaxis ; bronchospasm ; laryngeal oedema ; collapse ; convulsion encephalopathy within 72 hour 9 . Receipt live attenuate vaccine HIV envelope component within 60 day vaccine within 14 day enrolment 10 . Receipt experimental vaccine contain HIV envelope component time past 11 . Receipt blood product immunoglobulin within 4 month screen 12 . Participation another trial medicinal product , complete less 30 day prior enrolment . 13 . HIV 1 2 positive indeterminate screening . 14 . Positive hepatitis B surface antigen , hepatitis C antibody serology indicate active syphilis require treatment 15 . Grade 1 routine laboratory parameter . Hyperbilirubinaemia consider exclusion criterion confirm conjugated bilirubinaemia 16 . Current use electronic stimulation device , cardiac demand pacemaker , automatic implantable cardiac defibrillator , nerve stimulators , deep brain stimulators . 17 . Presence surgical traumatic metal implant sit administration 18 . Unable read speak English fluency level adequate full comprehension procedure require participation consent . 19 . Women history toxic shock syndrome . 20 . Women use intrauterine device contraception ( incompatible softcup sample ) 21 . Unlikely comply protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>safety</keyword>
	<keyword>immunogenicity</keyword>
	<keyword>HIV vaccine</keyword>
</DOC>